SEC Form 4Coverage since May 26, 2026
$RIGL insider trading
Over the last 12 months, Rigel Pharmaceuticals insiders reported no purchases and 2 sales totaling $160K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $160K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $RIGL · 12Mvia TradingView
Top insiders · 12m
Ali-Jackson Kamil—2× · $160K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Ali-Jackson KamilD | ▼ Sale | 2,500 | $35 | $88K | -19.8% | plan |
| May 26, 2026 | Ali-Jackson KamilD | ▼ Sale | 2,500 | $29.17 | $73K | -16.5% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RIGL feed.